Physician profile
Daniel Grabell
NPI 1851764336
$113,277.79
in general payments reported to CMS, 2019-2025
27 companies · $87K in 2025
The $87K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $360 · 2021: $475 · 2022: $478 · 2023: $365 · 2024: $24K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Consulting Fee: $25K · Travel and Lodging: $4,702 · Food and Beverage: $4,133 · Honoraria: $3,055 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,043.52 |
| Consulting Fee | $25,323.00 |
| Travel and Lodging | $4,702.34 |
| Food and Beverage | $4,133.42 |
| Honoraria | $3,055.30 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $56,771.76 | 2021-2025 | Nemluvio |
| Pfizer INC. | $28,573.68 | 2022-2025 | |
| Genzyme Corporation | $6,399.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $5,240.30 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,163.77 | 2023-2025 | Dupixent, Libtayo |
| Abbvie INC. | $3,145.72 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $3,091.86 | 2022-2025 | |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Amneal Pharmaceuticals LLC | $333.00 | 2024 | |
| Janssen Biotech, INC. | $325.62 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $288.33 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $264.21 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $180.90 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $124.99 | 2020 | |
| Lilly USA, LLC | $82.54 | 2021-2025 | Ebglyss, Taltz, Olumiant |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $70.00 | 2022 | |
| Mayne Pharma Commercial LLC | $66.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.14 | 2024-2025 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Ucb, INC. | $33.34 | 2023-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32.60 | 2024-2025 | Cabtreo |
| Amgen INC. | $27.65 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.22 | 2021 | |
| Botanix Sb INC | $16.43 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $15.82 | 2024 | Sotyktu |
| Almirall LLC | $14.92 | 2021 | |
| Organon LLC | $8.80 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Grabell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.